Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Codagenix Inc. maintains an active presence in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These actions are spread across 3 distinct examiners, indicating a diverse set of individual reviews. However, all the pending office actions are situated within 1 distinct art unit, suggesting a high degree of technical overlap in the company's current filings.
The busiest examiner, CHESTNUT, BARRY A, is responsible for 1 pending office action. This means that the workload is evenly distributed, with each of the 3 distinct examiners handling exactly 1 matter. This distribution requires the company to manage multiple separate examiner relationships simultaneously within the same technical field.
The concentration of the pending office actions in 1 distinct art unit allows for a unified technical strategy, even as the company interacts with multiple distinct examiners. Practitioners must ensure consistency in arguments across these matters, as they are likely being evaluated against similar prior art within the single art unit. The 3 pending office actions represent the current core of the company's biotechnology prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.5% | +6.4% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572482 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | KINSEY WHITE, NICOLE ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17621125 | ATTENUATED DENGUE VIRUSES | CHEN, STACY BROWN | 24d overdue |
| 18572482 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | KINSEY WHITE, NICOLE ERIN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18758660 | VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES | CHESTNUT, BARRY A | — | §112DP | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18572482 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | KINSEY WHITE, NICOLE ERIN | 1672 | §102§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 17621125 | ATTENUATED DENGUE VIRUSES | CHEN, STACY BROWN | 1672 | §112 | Final Rejection | 24d overdue | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial